Literature DB >> 34170344

Intraoperative ultrasound assessment of ureteral patency during pelvic surgery.

Alice Cola1, Marta Barba1, Matteo Frigerio2,3.   

Abstract

Ureteral injuries probably represent the most feared complication of benign hysterectomies. Lack of proper intraoperative detection causes diagnostic delay, which results in additional hospitalization, prolonged catheterization, and multiple additional procedures. However, the policy of universal cystoscopy is still under debate, owing to costs, increased operative time, lack of proper training, and risk of trauma. Intraoperative ultrasound assessment can offer a valid alternative for evaluating ureteral patency. After intravenous administration of 300 ml of saline solution and 10 mg of furosemide, the bladder is filled with 300 ml of saline solution. Transabdominal ultrasound bladder scans are obtained with a convex 3.5-MHz probe in transverse planes. The power Doppler field size is set to include the entire posterior wall of the bladder, at the level of the ureterovesical junctions. Ureteral patency test is considered normal if jets are present on both sides. It is considered abnormal when either absent or comparatively diminished on one side. It is considered nondiagnostic when neither side is visualized. Cystoscopy should be performed in the case of abnormal or nondiagnostic sonographic findings. Intraoperative transabdominal power Doppler ultrasound represents a feasible, non-invasive, and inexpensive diagnostic tool for assessing ureteral patency during gynecological surgery.
© 2021. The International Urogynecological Association.

Entities:  

Keywords:  Acute renal failure; Gynecological surgery; Prolapse surgery; Ultrasound; Ureteral patency

Mesh:

Year:  2021        PMID: 34170344     DOI: 10.1007/s00192-021-04901-z

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  7 in total

1.  Intraoperative and postoperative morbidity associated with cystoscopy performed in patients undergoing gynecologic surgery.

Authors:  Alex Ferro; David Byck; Donald Gallup
Journal:  Am J Obstet Gynecol       Date:  2003-08       Impact factor: 8.661

Review 2.  Outcomes of transvaginal uterosacral ligament suspension: systematic review and metaanalysis.

Authors:  Rebecca U Margulies; Mary A M Rogers; Daniel M Morgan
Journal:  Am J Obstet Gynecol       Date:  2010-02       Impact factor: 8.661

3.  The ability of renal ultrasound and ureteral jet evaluation to predict 30-day outcomes in patients with suspected nephrolithiasis.

Authors:  J Matthew Fields; Jonathan I Fischer; Kenton L Anderson; Alessandro Mangili; Nova L Panebianco; Anthony J Dean
Journal:  Am J Emerg Med       Date:  2015-07-17       Impact factor: 2.469

4.  Cystoscopy at the time of benign hysterectomy: a decision analysis.

Authors:  Douglas H Gilchrist-Scott; Margaret G Mueller; Kimberly S Kenton
Journal:  Am J Obstet Gynecol       Date:  2019-06-07       Impact factor: 8.661

5.  Universal cystoscopy at the time of benign hysterectomy: a debate.

Authors:  Lisa M Peacock; Amy Young; Rebecca G Rogers
Journal:  Am J Obstet Gynecol       Date:  2018-07       Impact factor: 8.661

6.  The incidence of urinary tract injury during hysterectomy: a prospective analysis based on universal cystoscopy.

Authors:  Babak Vakili; Ralph R Chesson; Brooke L Kyle; S Abbas Shobeiri; Karolynn T Echols; Richard Gist; Yong T Zheng; Thomas E Nolan
Journal:  Am J Obstet Gynecol       Date:  2005-05       Impact factor: 8.661

7.  Disability and litigation from urinary tract injuries at benign gynecologic surgery in Canada.

Authors:  Donna T Gilmour; Thomas F Baskett
Journal:  Obstet Gynecol       Date:  2005-01       Impact factor: 7.661

  7 in total
  1 in total

1.  Native-tissue prolapse repair: Efficacy and adverse effects of uterosacral ligaments suspension at 10-year follow up.

Authors:  Alice Cola; Giuseppe Marino; Rodolfo Milani; Marta Barba; Silvia Volontè; Federico Spelzini; Stefano Manodoro; Matteo Frigerio
Journal:  Int J Gynaecol Obstet       Date:  2022-02-08       Impact factor: 4.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.